Rapid sepsis test shortens hospital stays
A study published in the Archives of Pathology & Laboratory Medicine demonstrates the clinical and economic impact of implementing rapid sepsis diagnostic testing with Nanosphere‘s FDA-cleared Verigene Gram-Positive Blood Culture Test (BC-GP) in a pediatric patient population. The outcomes study was conducted at Children’s Hospital Los Angeles.
“Our study is the first to assess the clinical and economic impact of BC-GP in a pediatric population,” the hospital’s clinical microbiology director, Jennifer Dien Bard, PhD, said in a statement. “We saw a decrease in morbidity, mortality, length of stay, and hospital costs for pediatric patients with gram-positive bloodstream infections after implementing BC-GP.” Dr. Bard is the senior author of the paper (Felsenstein S, et al. 2016;140:267–75.)
The results of the study include: a 5.6-day median length-of-stay reduction for patients with S. aureus bloodstream infections (8.9 versus 14.7 days); a 1.9-day overall median hospital length-of-stay reduction per patient (7.2 versus 9.1 days); a 39.6-hour reduction in antimicrobial exposure for patients with contaminated blood cultures (28.1 versus 67.7 hours); and a 12.5-hour reduction in overall time to antimicrobial optimization (34.1 versus 46.6 hours).